Microbot Medical Inc. Common Stock (MBOT) Stock
NASDAQ · MBOT
Key stats
- Market cap
- $74.55M
- Price / Earnings ratio
- -4.3x
- EPS (TTM)
- -$0.24
- Volume
- Loading
- 52-week high
- $2.86
- 52-week low
- $0.93
Source: third-party data provider, as of November 13, 2026
Compare with MBOT
Recent news

Zacks Investment Research
Microbot Medical Inc. (MBOT) Reports Q2 Loss, Lags Revenue Estimates
MBOTAugust 11, 2026
Zacks Investment Research
Microbot Medical Inc. (MBOT) Reports Q2 Loss, Lags Revenue Estimates
MBOT

Zacks Investment Research
New Strong Buy Stocks for July 23rd
MBOTJuly 23, 2026
Zacks Investment Research
New Strong Buy Stocks for July 23rd
MBOT

Zacks Investment Research
After Plunging 22.6% in 4 Weeks, Here's Why the Trend Might Reverse for Microbot Medical (MBOT)
MBOTMay 19, 2026
Zacks Investment Research
After Plunging 22.6% in 4 Weeks, Here's Why the Trend Might Reverse for Microbot Medical (MBOT)
MBOT

Zacks Investment Research
Microbot Medical Inc. (MBOT) Reports Q1 Loss, Misses Revenue Estimates
MBOTMay 13, 2026
Zacks Investment Research
Microbot Medical Inc. (MBOT) Reports Q1 Loss, Misses Revenue Estimates
MBOT
Technical indicators
- RSI 14
- 51.41
- MACD 12/26/9
- -0.02
- EMA 9 of MACD
- -0.04
- MACD histogram
- 0.02
- SMA 50
- $1.18
- Price below SMA 50
- EMA 50
- $1.19
- Price below EMA 50
- SMA 200
- $1.81
- Price below SMA 200
- EMA 200
- $1.70
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Strong Sell0
Sell0
Hold0
Buy3
Strong Buy0
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Revenue
Net income
Net margin %
2021
2022
2023
2024
2025
0000
Debt & Balance Sheet
Total assets
Total liabilities
2021
2022
2023
2024
2025
98M65M32M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-13.1M
Net incomeEarnings
No data available
Source: third-party data provider
Latest news

Zacks Investment Research
Microbot Medical Inc. (MBOT) Reports Q2 Loss, Lags Revenue Estimates
MBOTAugust 11, 2026
Zacks Investment Research
Microbot Medical Inc. (MBOT) Reports Q2 Loss, Lags Revenue Estimates
MBOT

Zacks Investment Research
New Strong Buy Stocks for July 23rd
MBOTJuly 23, 2026
Zacks Investment Research
New Strong Buy Stocks for July 23rd
MBOT

Zacks Investment Research
After Plunging 22.6% in 4 Weeks, Here's Why the Trend Might Reverse for Microbot Medical (MBOT)
MBOTMay 19, 2026
Zacks Investment Research
After Plunging 22.6% in 4 Weeks, Here's Why the Trend Might Reverse for Microbot Medical (MBOT)
MBOT

Zacks Investment Research
Microbot Medical Inc. (MBOT) Reports Q1 Loss, Misses Revenue Estimates
MBOTMay 13, 2026
Zacks Investment Research
Microbot Medical Inc. (MBOT) Reports Q1 Loss, Misses Revenue Estimates
MBOT

Zacks Investment Research
Stryker to Report Q1 Earnings: What's in Store for the Stock?
MBOTApril 28, 2026
Zacks Investment Research
Stryker to Report Q1 Earnings: What's in Store for the Stock?
MBOT

Zacks Investment Research
Microbot Medical Begins Full U.S. Launch of LIBERTY System
MBOTApril 15, 2026
Zacks Investment Research
Microbot Medical Begins Full U.S. Launch of LIBERTY System
MBOT

Stocktwits
MBOT Stock Falls As Investors Ponder Impact Of Geopolitical Tensions On Israel-Founded Company
MBOTMarch 3, 2026
Stocktwits
MBOT Stock Falls As Investors Ponder Impact Of Geopolitical Tensions On Israel-Founded Company
MBOT

InvestorPlace
3 Stocks at the Forefront of Medical Robotics
MBOTDecember 10, 2023
InvestorPlace
3 Stocks at the Forefront of Medical Robotics
MBOT

PennyStocks
How to Handle Penny Stocks Volatility in 2023
MBOTMay 23, 2023
PennyStocks
How to Handle Penny Stocks Volatility in 2023
MBOT
About Microbot Medical Inc. Common Stock
No description available.
SectorHealthcare
IndustryMedical Devices
Employees43
CEOMr. Harel Gadot
IPO DateMar 25, 1992
HeadquartersHingham, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Harel Gadot | Co-Founder, President, CEO & Chairman | 1973 |
| Ms. Rachel Vaknin | Chief Financial Officer | 1979 |
| Dr. Simon Sharon MBA, MSc | CTO & GM of Microbot Israel | 1960 |
| Dr. Juan Diaz-Cartelle | Chief Medical Officer | 1976 |
| Ms. Christina Bailey | Vice President of Sales | — |
| Ms. Allison Rosefort | Vice President of Marketing | — |
| Naama Moav | Vice President of Human Resources | — |
| Mr. Michael Lytle | Head of Sales Operations & Analytics | — |
Fundamentals
Valuation
Price-to-sales ratio203.76
Price-to-book value1.02
PEG ratio0.70
Profitability
Return on Equity-22.00%
Return on Assets-21.00%
Return on Sales-4722.00%
Gross margin (latest quarter)-266.80%
EBITDA$-16.29M
Trading
Average volume865,285
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 51.41
- MACD 12/26/9
- -0.02
- EMA 9 of MACD
- -0.04
- MACD histogram
- 0.02
- SMA 50
- $1.18
- Price below SMA 50
- EMA 50
- $1.19
- Price below EMA 50
- SMA 200
- $1.81
- Price below SMA 200
- EMA 200
- $1.70
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Analyst consensus:Buy
100% Buy
0% Hold
0% Sell
Analyst price target
- Low
- $2.50
- Average
- $6.17
- High
- $12.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -25.8 | +47.9 | ||||||||||
| 2022 | -23.8 | -8.8 | +12.0 | -6.4 | -0.2 | -11.6 | -0.2 | +0.0 | -2.8 | -17.6 | +23.0 | -34.4 |
| 2023 | -2.8 | -8.7 | -25.7 | -27.9 | +39.0 | +25.9 | -18.0 | -9.9 | -36.5 | -11.8 | +5.9 | +27.1 |
| 2024 | -3.0 | -0.8 | -5.4 | -30.8 | +4.2 | -26.1 | -1.0 | -9.3 | +2.3 | +8.0 | +2.1 | +12.0 |
| 2025 | +61.4 | -22.1 | +11.0 | +65.8 | +5.0 | -5.6 | +1.6 | +49.4 | -18.7 | -29.4 | +14.2 | -11.5 |
| 2026 | -14.7 | +35.4 | -2.8 | -11.8 | -3.3 | -1.5 | -9.9 | -15.8 | -18.4 | -9.2 | +6.7 |
Compare stocks
Market cap
$74.55M
-
-
-
Price / Earnings ratio
-4.30
-
-
-
Price / Sales ratio
203.76
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
865,285
-
-
-
Earnings per share
$-0.24
-
-
-



